VIRP Virbac SA

Virbac: erratum short Press release Capital reduction_September 13, 2024

Virbac: erratum short Press release Capital reduction_September 13, 2024

This press release rectifies the version of the press release issued by Virbac on September 13, 2024 at 5:45 pm in order to correct a typing error in the amount of Virbac's new share capital.

The share capital of Virbac amounts now to €10,488,325 and not €10,448,325 as announced.

Focusing on animal health, from the beginning

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals’ quality of life and to shaping together the future of animal health.

Press contacts - Agence Libremullenlowe

 



Anne Da Silva Passos - - 28



 

Attachment



EN
16/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Virbac SA

 PRESS RELEASE

Virbac : Declaration of the number of shares and voting rights 10/2024

Virbac : Declaration of the number of shares and voting rights 10/2024 DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsOctober, 31 20248 390 660Gross total of voting rights : 12 707 824Net total* of voting rights : 12 691 7...

Charlotte Vaisse ... (+3)
  • Charlotte Vaisse
  • Jerôme Bodin
  • Marc Lavaud

ODDO BHF Small & MIDCAP MORNING NEWS - 10/18/2024

The recovery in growth in the IT & engineering services sector is undermined by the still mixed macroeconomic climate and the setbacks in the automotive and aerospace sectors. The improvement in sector momentum will therefore be minimal in H2 2024 with a growing decorrelation between the US which should be robust and a stagnating Europe. This leads us to adopt a more cautious approach on companies in our sector (revision to our 2025 growth estimates for 12 companies) and to prefer Acc...

Charlotte Vaisse ... (+3)
  • Charlotte Vaisse
  • Jerôme Bodin
  • Marc Lavaud

ODDO BHF Small & MIDCAP MORNING NEWS - 18/10/2024

La reprise de la croissance du secteur IT & Engineering Services est mise à mal par un contexte macro toujours mitigé et par les déboires des secteurs Auto et Aéro. Ainsi, l’amélioration de la dynamique du secteur sera minimale au S2 2024 et probablement aussi au S1 2025, avec une décorrélation grandissante entre les US qui devraient être solides et une Europe stagnante. Ceci nous amène à adopter une approche plus prudente pour les sociétés de notre secteur (révision de croissance 202...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Virbac : CA T3 2024 : pas mieux que prévu / pas d’effet momentum

>T3 : +7,7% et +3,4% à ptcc. (vs +15,2% et +11,3% à ptcc. au S1) - Le CA T3 de Virbac atteint 339 M€, ie. +7,7% (+3,4% à ptcc. vs +5%e attendu par nous). Globion et Sasaeah contribuent à hauteur de 6,5 pt. A 9 mois, le CA se monte à 1 042,1 M€ (+12,6%) avec un CA Animaux de compagnie à +11,9% et un CA Animaux d’élevage à +3,2%. Virbac confirme sa guidance ie. une croissance du CA comprise entre 7% et 9%, +5,5% d’effet périmètre (soit à périmètre réel, entre ...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Virbac : Q3 2024 sales: no better than expected / no momentum effect

>Q3: +7.7% and +3.4% l-f-l (vs +15.2% and +11.3% l-f-l in H1) - Virbac’s Q3 sales totalled € 339m, i.e. +7.7% (+3.4% l-f-l vs our forecast of +5%e). Globion and Sasaeah contributed 6.5 points. At 9M, sales stand at € 1,042.1m (+12.6%) with pet sales at +11.9% and livestock sales at +3.2%. Virbac confirmed its guidance of sales growth of 7-9%, a +5.5% scope effect (at real scope, between +12.5% and +14.5%) and an EBIT ratio around 16% of sales.A ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch